D
Donna M. Weber
Researcher at University of Texas MD Anderson Cancer Center
Publications - 295
Citations - 14527
Donna M. Weber is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 55, co-authored 269 publications receiving 13462 citations. Previous affiliations of Donna M. Weber include Celgene & Lund University.
Papers
More filters
Journal ArticleDOI
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle,J. Anthony Child,Kenneth C. Anderson,Bart Barlogie,Régis Bataille,William I. Bensinger,Joan Bladé,Mario Boccadoro,William S. Dalton,Meletios A. Dimopoulos,Benjamin Djulbegovic,Mark T. Drayson,Brian G.M. Durie,Thiery Facon,Rafael Fonseca,Gösta Gahrton,Philip R. Greipp,Jean Luc Harousseau,David P. Harrington,Mohamad A. Hussein,Douglas E. Joshua,Heinz Ludwig,Gareth J. Morgan,Martin M. Oken,R. L. Powles,Paul G. Richardson,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Chaim Shustik,Bhawna Sirohi,Pieter Sonneveld,Guido J Tricot,Ingemar Turesson,Brian G Van Ness,David H. Vesole,Donna M. Weber,Jan Westin,Keith Wheatley +38 more
TL;DR: The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data.
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Donna M. Weber,Christine Chen,Ruben Niesvizky,Michael Wang,Andrew Belch,Edward A. Stadtmauer,David S. Siegel,Ivan Borrello,S. Vincent Rajkumar,Asher A. Chanan-Khan,Sagar Lonial,Zhinuan Yu,John Patin,Marta Olesnyckyj,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide plus dexamethasone is superior to placebo plus DexamethAsone in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Antonio Palumbo,S V Rajkumar,Meletios A. Dimopoulos,Paul G. Richardson,J F San Miguel,Bart Barlogie,J L Harousseau,Jeffrey A. Zonder,Michele Cavo,Maurizio Zangari,M. Attal,Andrew Belch,S. Knop,Douglas E. Joshua,Orhan Sezer,Heinz Ludwig,David H. Vesole,J. Bladé,Robert A. Kyle,Jan Westin,Donna M. Weber,Sara Bringhen,Ruben Niesvizky,Anders Waage,M. von Lilienfeld-Toal,Sagar Lonial,Gareth J. Morgan,Robert Z. Orlowski,Kazuyuki Shimizu,KC Anderson,Mario Boccadoro,Brian G.M. Durie,Pieter Sonneveld,Mohamad A. Hussein +33 more
TL;DR: This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model for venous thromboembolism (VTE), and recommends low-molecular-weight heparin (LMWH), warfarin or aspirin.
Journal ArticleDOI
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
TL;DR: Thalidomide alone was effective in patients with newly diagnosed myeloma and the combination with dexamethasone induced a high frequency of response, rapid onset of remission, and low incidence of serious irreversible toxicity.
Journal ArticleDOI
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Meletios A. Dimopoulos,Christine Chen,Andrew Spencer,Ruben Niesvizky,M. Attal,Edward A. Stadtmauer,Maria Teresa Petrucci,Zhinuan Yu,Marta Olesnyckyj,J. Zeldis,Robert Knight,Donna M. Weber +11 more
TL;DR: Data confirm the significant response and survival benefit with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and low β2-microglobulin and low bone marrow plasmacytosis were associated with longer survival.